VF
RNAC icon

Virtu Financial’s Cartesian Therapeutics RNAC Stock Holding History

Virtu Financial’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,956
Closed -$61K – 1986
2023
Q4 		$61K Buy
+2,956
New +$88.2K ﹤0.01% 1142
2023
Q3 		– Sell
-1,859
Closed -$62K – 1797
2023
Q2 		$62K Buy
+1,859
New +$66.5K ﹤0.01% 1112
2022
Q4 		– Sell
-764
Closed -$38K – 2062
2022
Q3 		$38K Buy
+764
New +$42K ﹤0.01% 1258
2022
Q1 		– Sell
-1,878
Closed -$184K – 1952
2021
Q4 		$184K Buy
1,878
+210
+13% +$22.6K 0.02% 868
2021
Q3 		$208K Sell
1,668
-263
-14% -$31.8K 0.02% 904
2021
Q2 		$242K Buy
+1,931
New +$230K 0.02% 860
2021
Q1 		– Sell
-453
Closed -$41K – 1959
2020
Q4 		$41K Buy
453
+34
+8% +$2.95K ﹤0.01% 1260
2020
Q3 		$31K Sell
419
-476
-53% -$36.5K 0.01% 882
2020
Q2 		$76K Buy
+895
New +$81.1K 0.01% 940
2018
Q1 		– Sell
-1,040
Closed -$306K – 2493
2017
Q4 		$306K Buy
+1,040
New +$454K 0.02% 1253

Other funds holding RNAC

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Virtu Financial's RNAC Position: Q1 2024 in Review

Virtu Financial sold out of Cartesian Therapeutics (RNAC) in Q1 2024, closing a stake of 2,956 shares — an estimated $61K sold.

Virtu Financial first reported a position in RNAC in Q4 2017 and held it in 10 quarters. The position peaked at $306K in Q4 2017. 69 funds tracked by Wall St. Rank hold RNAC as of Q1 2024.

  • Virtu Financial reported no remaining Cartesian Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Virtu Financial sold 2,956 Cartesian Therapeutics shares in Q1 2024, an estimated $61K.
  • Virtu Financial first reported a position in Cartesian Therapeutics in Q4 2017 and held it in 10 quarters.
  • Virtu Financial's Cartesian Therapeutics position peaked at $306K in Q4 2017.
  • 69 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2024.

Based on Virtu Financial's 13F filing for Q1 2024, filed 20 May 2024.